---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213267"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:06:36.155868+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q1 revenue falls 10% to $47.2M; net loss widens to $18.0M

## Summary
- Revenue $47.2M (-10% YoY); net loss $18.0M ($0.28 loss per share) vs $15.9M loss ($0.25) in Q1 2025.
- Adjusted EBITDA loss of $5.5M vs $(3.8)M prior year; gross margin 79.3% nearly flat.
- Cash, equivalents, and marketable securities $51.9M, up $3.5M from Dec 2025; $115M credit facility available.
- FY2026 revenue guidance reaffirmed at $202-212M (decline 5% to 0%); adjusted EBITDA loss expected $4-6M.
- CEO cites continued market share gains and case volume growth; initiated limited release of SuperBite Compression Screw System.

## SEC filing metadata
- accession: 0001193125-26-213267
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000119312526213267/0001193125-26-213267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000119312526213267/tmci-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213267
- JSON: https://secwatch.observer/filing/0001193125-26-213267.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213267.txt

## Source-grounded claims
- claim_id: fb43ec664b49f588b2d690618c79b8026b93ccb0
  claim: TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2026 results: revenue $47.2 million, net income $(18.0) million, EPS $(0.28) per share. Guidance reaffirmed.
  evidence_excerpt: treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. • Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000119312526213267/0001193125-26-213267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.